Andere Sprachen PTC Therapeutics, Inc.

Aktien

A1W0MW

US69366J2006

PTCT

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 24.04.2024			% 5 Tage	% 1. Jan.
25.21 ^USD	-0.67%		+0.20%	-8.53%

28.03.	PTC Therapeutics beantragt EMA-Marktzulassung für Sepiapterin zur Behandlung von Phenylketonurie	MT
28.03.	PTC Therapeutics, Inc. kündigt Einreichung des Sepiapterin MAA zur Behandlung von PKU bei der EMA an	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)	24.04.
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	23.04.
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results	12.04.
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results	11.04.
PTC Therapeutics Seeks EMA Marketing Authorization for Sepiapterin for Phenylketonuria Treatment	28.03.
PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA	28.03.
PTC Therapeutics, Inc. Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA	28.03.
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza as a Treatment for AADC Deficiency	20.03.
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza? as a Treatment for AADC Deficiency	19.03.
PTC Therapeutics Provides Key Regulatory Updates	19.03.
PTC Therapeutics Shares Jump Following Q4 Results	01.03.
PTC Therapeutics Q4 Loss Narrows, Sales Up; Sets Guidance; Shares Slump After-Hours	29.02.
PTC Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29.02.
PTC Therapeutics: Q4 Earnings Snapshot	29.02.
PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024	29.02.
Earnings Flash (PTCT) PTC THERAPEUTICS Posts Q4 Revenue $307.1M, vs. Street Est of $317.9M	29.02.
PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results	29.02.
PTC Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29.02.
PTC Therapeutics to Participate at Upcoming Investor Conferences	27.02.
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	22.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen PTC Therapeutics, Inc.

Aktien

A1W0MW

US69366J2006

PTCT

Andere Sprachen

Filter